Ulotaront, a Trace Amine-Associated Receptor 1/Serotonin 5-HT 1A Agonist, in Patients With Parkinson Disease Psychosis
Open Access
- 1 August 2023
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 13 (4) , e200175
Abstract
Background and Objectives Ulotaront (SEP-363856) is a trace amine-associated receptor 1 agonist with 5-HT1A receptor agonist activity currently in phase 3 clinical development for the treatment of schizophrenia. In this exploratory, flexibly dosed study, ulotaront was evaluated for the treatment of Parkinson disease psychosis (PDP). Methods Patients with PDP requiring antipsychotic therapy were randomized, double-blind to ulotaront (25, 50, or 75 mg/d) or placebo. Mixed Model for Repeated Measures was used to assess change from baseline in the Scale for the Assessment of Positive Symptoms for Parkinson Disease (SAPS-PD) at 6 weeks (primary end point). Results The efficacy analysis sample comprised 38 patients (ulotaront, n = 24; placebo, n = 14). SAPS-PD total scores were numerically reduced in ulotaront-treated vs placebo-treated patients from week 1 to week 6: Least squares mean (95% confidence interval) difference in change from baseline at week 6 was −1.1 (−6.5, 4.3, p = 0.681). PDP symptom complete remission (≥100% improvement [reduction] from baseline in SAPS-PD total score) was observed in 25% of ulotaront-treated vs 0% of placebo-treated patients. SAPS-PD and Neuropsychiatric Inventory hallucinations subscales were numerically reduced vs placebo, and SAPS-PD total scores were reduced in patients with greater cognitive impairment (baseline Mini-Mental State Examination [MMSE] scores ≤24). Ulotaront improved Scales for Outcomes in Parkinson Disease Sleep Scale – Daytime Sleepiness scores (p = 0.022). There was no worsening of Unified Parkinson Disease Rating Scale Part III motor score, MMSE, or vital signs. Adverse events (≥10%) with ulotaront vs placebo included hallucinations (24% vs 14%), confusional state (20% vs 14%), dizziness (16% vs 7%), nausea (12% vs 7%), and falls (12% vs 21%). Discussion In this exploratory pilot study, ulotaront may decrease PDP symptoms without worsening motor function, particularly in patients with cognitive impairment. Trial Registration Information ClinicalTrials.gov identifier: NCT02969369; submitted: November 17, 2016; study start date: December 31, 2016. Classification of Evidence This Class II study was an exploratory pilot study that was underpowered to detect a statistically significant difference between ulotaront and placebo in the treatment of patients with Parkinson disease psychosis without worsening motor function.Keywords
This publication has 47 references indexed in Scilit:
- Psychosis in Parkinson's disease without dementia: Common and comorbid with other non‐motor symptomsMovement Disorders, 2012
- Psychosis associated to Parkinson's disease in the early stages: relevance of cognitive decline and depressionJournal of Neurology, Neurosurgery & Psychiatry, 2011
- Parkinson’s PsychosisCurrent Treatment Options in Neurology, 2010
- The scientific and clinical basis for the treatment of Parkinson disease (2009)Neurology, 2009
- Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stressJournal of Neurology, Neurosurgery & Psychiatry, 2007
- Effectiveness of Antipsychotic Drugs in Patients with Chronic SchizophreniaNew England Journal of Medicine, 2005
- Double‐blind, placebo‐controlled, unforced titration parallel trial of quetiapine for dopaminergic‐induced hallucinations in Parkinson's diseaseMovement Disorders, 2005
- Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow upJournal of Neurology, Neurosurgery & Psychiatry, 2004
- Longitudinal outcome of Parkinson’s disease patients with psychosisNeurology, 2003
- Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.Journal of Neurology, Neurosurgery & Psychiatry, 1992